Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

U.S. cancels COVID-19 vaccine contract with Emergent BioSolutions

By Brian Buntz | November 5, 2021

Emergent BiosolutionsEmergent BioSolutions (NYSE:EBS) saw its stock plunge today after the U.S. nixed a contract to manufacture COVID-19 vaccine doses for Johnson & Johnson (NYSE:JNJ).

Earlier this year, the company disposed of tens of millions of COVID-19 vaccine doses after identifying a manufacturing error in a Baltimore plant.

FDA released a scathing inspection report related to the plant in April, while Johnson & Johnson promised to increase oversight of the facility.

Emergent noted that it would not receive $180 million worth of the $628 million it had planned on getting from the COVID-19 vaccine contract.

Emergent also produces anthrax vaccine for the U.S. government and stated in an investor’s note that it remains “ready to continue supporting the USG’s priorities to protect the American public against public health threats.”

The company had also planned on manufacturing AstraZeneca’s vaccine in the same facility, but the U.S. government asked AstraZeneca to manufacture its vaccine elsewhere. AstraZeneca COVID-19 vaccine is not currently authorized for use in the U.S.

Emergent said it would continue to assist Johnson & Johnson in manufacturing other vaccines at the Baltimore plant.

The company said it had contributed more than 100 million dose equivalents of a COVID-19 vaccine for global distribution as of the end of September.

In the aforementioned investor’s note, the company stressed that its “business remains durable, resilient and poised for growth in line with [its] strategy,” which includes organic growth and acquisitions.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Pfizer logo
Pfizer CEO tests positive for COVID-19
Pfizer logo
Pfizer and BioNTech seek EMA authorization for COVID-19 vaccination in young children
Pfizer logo
FDA allows pharmacists to prescribe Paxlovid 
vaccine
Will COVID-19 vaccines be updated by fall? 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards